Skip to main content
Premium Trial:

Request an Annual Quote

Audere Gets FDA Emergency Use Authorization for SARS-CoV-2 At-Home Sample Collection Kit

NEW YORK — The US Food and Drug Administration on Tuesday granted Emergency Use Authorization for an at-home sample collection kit for SARS-CoV-2 molecular testing developed by nonprofit digital health firm Audere.

The [email protected] kit is designed for the self-collection of anterior nasal swab specimens by individuals aged 16 and older, as well as the collection of samples by adults in individuals aged 2 and older. Samples can be transported at ambient temperatures for in vitro diagnostic SARS-CoV-2 RNA testing.

Testing of [email protected] samples is limited to Audere-designated labs that are CLIA-certified to perform high-complexity tests, according to the FDA.

In addition to the sample collection kit, Seattle-based Audere has developed a COVID-19 symptom tracking and surveillance tool that is currently used by a local fire department.

The Scan

Sensor to Spot SARS-CoV-2 Exposure

Yale researchers have developed a sensor that gauges SARS-CoV-2 exposure, according to the New Haven Register.

Watching BA.2

A subtype of the Omicron SARS-CoV-2 variant has been found in a number of countries, the Washington Post says.

Vermont Weighs Genetic Discrimination Bill

VT Digger reports Vermont legislators are considering a bill to bar insurer from denying customers coverage based on genetic information.

PNAS Papers on Convergent Pathogen Effectors, Lineage-Related RNA Mutations, Desiccation-Tolerant Grass

In PNAS this week: convergent evolution of pathogen effectors, algorithm to identify cell lineage features, and more.